Research programme: cachexia and anorexia therapeutics - Obexia

Drug Profile

Research programme: cachexia and anorexia therapeutics - Obexia

Alternative Names: 1E8a scFv; OBX 1201; OBX 1202

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Obexia
  • Class Monoclonal antibodies
  • Mechanism of Action Melanocortin type 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anorexia; Cachexia

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Anorexia in Switzerland (IV)
  • 28 Apr 2018 No recent reports of development identified for preclinical development in Cachexia in Switzerland (IV)
  • 26 Sep 2016 Research programme: cachexia and anorexia therapeutics - Obexia is available for licensing as of 26 Sep 2016. http://obexia.com/about.php
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top